glp-1 receptor agonists should be avoided in patients with and next-generation metabolic hormone therapies chronic kidney disease Updated guidance for patients using
Description
doi: 10.1016/S2213-8587(19)30249-9

Use features like bookmarks, note taking and highlighting while reading Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide to Weight Loss, Appetite Control & Metabolic Reset.

iNKT: invariant natural killer T
NAFLD Consensus Consortium

Nat Rev Dis Primers (2016) 2:16057
